Skip to main content

Featured

New harbourfront space opens

The Development Bureau announced that the Pierside Precinct near Wan Chai Ferry Pier further opened today, providing a nostalgic harbourfront leisure space with a panoramic view of Victoria Harbour for the public.   Being the 12th harbourfront leisure space that opened since October last year, the newly opened area is located to the east of the ferry pier on a harbour site reclaimed for the construction of the Central-Wan Chai Bypass.   The bureau said under the incremental approach, a 180-metre-long promenade of the precinct opened earlier in March, followed by the opening of a further 80m in October.   With an area of about 4,600 sq m, the newly opened part has almost doubled the precinct's original space.   In contrast to the colourful cartoon style adopted at other harbourfront sites opened earlier in Western District and Wan Chai, the precinct mainly comprises simple fair-faced concrete and wooden structures.   It features a stylish touch with its clear and rectiline

Vaccine recommendations published

The two scientific committees under the Centre for Health Protection convened a meeting today to provide recommendations on the use of COVID-19 vaccination for those with previous COVID-19 infection.   Joined by the Chief Executive’s expert advisory panel, the committees also discussed the existing evidence on COVID-19 vaccine effectiveness against different variants.       The meeting noted that previous COVID-19 infection usually confers immunity for at least six to nine months for the majority of patients. There is accumulating evidence showing that those previously infected with COVID-19 would be further protected by one dose of mRNA vaccines.   After receiving one dose of mRNA vaccine, these people may experience more systemic side effects, such as fatigue, headache, chills, muscle pain, fever and joint pain, when compared to those without prior infection.   People who wish to receive the mRNA vaccine should wait for at least 90 days after discharge from previous infection.   The meeting also noted that in general, studies have shown that the existing vaccines work well against the non-variant. The effectiveness data against variants differ by vaccines.   The Fosun Pharma/BioNTech vaccine is effective against the variants which first emerged in the UK and Brazil, but is less effective against the South African one.   There is currently limited efficacy data of CoronaVac developed by Sinovac Biotech (Hong Kong) against variants.   The vaccine developed by AstraZeneca in collaboration with the University of Oxford is effective against the UK variants but is ineffective against the South African one.   The meeting also agreed that the combination of non-pharmaceutical interventions with vaccination will allow for maximum protection against the virus. There is a need to continue social distancing, good hand hygiene and wearing a mask in public to reduce the risk of transmission.
http://dlvr.it/Rvxr2J

Popular Posts